Results 121 to 130 of about 99,253,553 (299)
A Scalable Synthesis of an Azabicyclooctanyl Derivative, a Novel DPP-4 Inhibitor
, 2016 A practical synthetic strategy to a chiral azabicycclooctanyl derivative (1), a potent DPP-4 inhibitor, starting from a commercially available nortropine is described.
Chuanqin Liu (2407684) +11 more
core +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo +12 more
wiley +1 more source
Risk of hyperkalaemia in patients with type 2 diabetes mellitus prescribed with SGLT2 versus DPP-4 inhibitors [PDF]
To investigate the risk of hyperkalaemia in new users of sodium–glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP-4) inhibitors among patients with type 2 diabetes mellitus (T2DM).
Tsang, Christopher Tze Wei +13 more
core +1 more source
New Plant Protection, EarlyView.Despite 17 years of development, the effectiveness of nanocarrier‐delivered RNAi pesticide (NDRP) for agricultural biological control remains limited. The successful development of effective NDRP development requires the coordinated optimization of target gene selection and nanocarrier properties, including RNA dosage, multi‐gene targeting, protection ...
Shi Dong Wang +4 more
wiley +1 more source
Periodontitis and metabolic diseases (diabetes and obesity): Tackling multimorbidity
Periodontology 2000, EarlyView., 2023 Abstract Noncommunicable diseases (NCDs) are multifactorial, long‐term, chronic conditions that represent a burden to health‐care systems worldwide as they can only be controlled rather than cured; hence, they require long‐term care. With the exponential increase in NCDs, the occurrence of individuals presenting with more than one chronic disease is ...
Crystal Marruganti +2 more
wiley +1 more source
Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis
VIEW, EarlyView.In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian +5 more
wiley +1 more source
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
, 2009 Type 2 diabetes mellitus (T2DM) is a global epidemic with increasing impact on individuals and healthcare providers. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting ...
Piya, Milan K +10 more
core +1 more source
BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.ABSTRACT Objective An increasing number of women of childbearing age worldwide are using glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and are advised to use effective contraception during treatment. Nevertheless, maternity services are encountering increasing numbers of women exposed to GLP‐1 RAs shortly before conception or during pregnancy ...
Katherine G. Y. Lau +6 more
wiley +1 more source
Alogliptin benzoate for management of type 2 diabetes
Vascular Health and Risk Management, 2015 Yoshifumi Saisho Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan Abstract: Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress ...
Saisho Y
doaj